Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gelsolin - BioAegis Therapeutics

Next Previous
Drug Profile

Gelsolin - BioAegis Therapeutics

Alternative Names: Gelsolin recombinant; hu r-P gelsolin; pGSN; Recombinant human plasma gelsolin; rh gelsolin; rhu-pGSN; Solinex

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brigham and Womens Hospital
  • Developer BioAegis Therapeutics; Critical Biologics Corporation
  • Class Anti-inflammatories; Antibacterials; Antifibrotics; Antineoplastics; Bronchodilators; Expectorants; Proteins
  • Mechanism of Action Interleukin 1 beta inhibitors; Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adult respiratory distress syndrome; COVID-19 pneumonia
  • Phase I/II Community-acquired pneumonia
  • No development reported Inflammation
  • Discontinued Bronchitis; Cystic fibrosis; Systemic inflammatory response syndrome

Most Recent Events

  • 17 Jun 2025 Gelsolin - BioAegis Therapeutics receives Fast Track designation for Adult respiratory distress syndrome [IV] in USA
  • 15 Jun 2025 BioAegis Therapeutics and University of Maryland School of Medicine plan a phase II trial for Decompression sickness (In volunteers) (IV) in June 2025 (NCT06216366)
  • 28 May 2025 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top